- Home
- PC vs CTXR Comparison
PC vs CTXR Comparison
Compare PC & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PC
- CTXR
- Stock Information
- Founded
- PC 2012
- CTXR 2007
- Country
- PC Singapore
- CTXR United States
- Employees
- PC N/A
- CTXR N/A
- Industry
- PC Restaurants
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- PC Consumer Discretionary
- CTXR Health Care
- Exchange
- PC Nasdaq
- CTXR Nasdaq
- Market Cap
- PC 74.4M
- CTXR 84.9M
- IPO Year
- PC 2024
- CTXR N/A
- Fundamental
- Price
- PC $3.00
- CTXR $0.41
- Analyst Decision
- PC
- CTXR Strong Buy
- Analyst Count
- PC 0
- CTXR 2
- Target Price
- PC N/A
- CTXR $5.00
- AVG Volume (30 Days)
- PC 237.3K
- CTXR 1.1M
- Earning Date
- PC 11-15-2024
- CTXR 08-12-2024
- Dividend Yield
- PC N/A
- CTXR N/A
- EPS Growth
- PC N/A
- CTXR N/A
- EPS
- PC N/A
- CTXR N/A
- Revenue
- PC $4,118,064.00
- CTXR N/A
- Revenue This Year
- PC N/A
- CTXR N/A
- Revenue Next Year
- PC N/A
- CTXR N/A
- P/E Ratio
- PC N/A
- CTXR N/A
- Revenue Growth
- PC N/A
- CTXR N/A
- 52 Week Low
- PC $3.00
- CTXR $0.34
- 52 Week High
- PC $5.73
- CTXR $1.07
- Technical
- Relative Strength Index (RSI)
- PC N/A
- CTXR 38.61
- Support Level
- PC N/A
- CTXR $0.34
- Resistance Level
- PC N/A
- CTXR $0.41
- Average True Range (ATR)
- PC 0.00
- CTXR 0.04
- MACD
- PC 0.00
- CTXR 0.00
- Stochastic Oscillator
- PC 0.00
- CTXR 36.59
About PC Premium Catering (Holdings) Limited Ordinary Shares
Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. They specialize in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.